Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial

References

• Comings DE. Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann N Y Acad Sci 2001; 931: 50–83
   PubMed Web of Science ®Google Scholar
• Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. J Am Med Assoc 1998; 279: 1100–1107
   PubMed Web of Science ®Google Scholar
• Biederman J, Spencer TJ. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999; 46: 1234–1242
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders4th edn. American Psychiatric Association, Washington, DC 2000
   Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol 2002; 111: 279–289
   PubMed Web of Science ®Google Scholar
• Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148: 564–577
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S. Long-term outcome of hyperactive children: a review. J Am Acad Child Adolesc Psychiatrics 1991; 30: 383–387
   PubMed Web of Science ®Google Scholar
• MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999; 56: 1073–1086
   PubMed Web of Science ®Google Scholar
• Ferris RM, Tang FL. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of I-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther 1979; 210: 422–428
   PubMed Web of Science ®Google Scholar
• Dodson WW. Pharmacotherapy of adult ADHD. J Clin Psychol 2005; 61: 589–606
   PubMed Web of Science ®Google Scholar
• Holman RB. Biological effects of central nervous system stimulants. Addiction 1994; 89: 1435–1441
   PubMed Web of Science ®Google Scholar
• Greenhill L. Attention-deficit/hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin N Am 1995; 4: 123–168
   Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699–711
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–432
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002; 63: 16–22
   PubMed Web of Science ®Google Scholar
• Popper CW. Antidepressants in the treatment of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1997; 58: 14–29
   PubMed Web of Science ®Google Scholar
• Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004; 114: e1–e8
   PubMed Web of Science ®Google Scholar
• Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend 2002; 67: 149–156
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose–response study. Pediatrics 2001; 108: E83
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896–1901
   PubMed Web of Science ®Google Scholar
• Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63: 1140–1147
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112–120
   PubMed Web of Science ®Google Scholar
• Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005; 44: 647–655
   PubMed Web of Science ®Google Scholar
• Starr HL, Kemner J. Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. J Nat Med Assoc 2005; 97(Suppl 10)11S–16S
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776–784
   PubMed Web of Science ®Google Scholar
• Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36: 980–988
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale-IV checklists, norms, and clinical interpretation. The Guilford Press, New York 1998; 28–42
   Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology, revised. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD 1976; 217–222
   Google Scholar
• Conners CK. Conners’ rating scales-revised, technical manual. Multi-Health Systems, Toronto, Ontario 1997
   Google Scholar
• Biederman J, Heiligenstein JH, Faries DE, et al. (Atomoxetine ADHD Study Group). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics 2002; 110: e75
   PubMed Web of Science ®Google Scholar
• Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155: 693–695
   PubMed Web of Science ®Google Scholar
• Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacology 2001; 11: 167–170
   PubMed Web of Science ®Google Scholar
• Stein MA, Blondis TA, Schnitzler ER, et al. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 1996; 98: 748–756
   PubMed Web of Science ®Google Scholar
• Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001; 107: E105
   Web of Science ®Google Scholar
• Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116: e74–e80
   PubMed Web of Science ®Google Scholar
• Brown WJ, Biederman J, Spencer T, et al. Efficacy and safety of atomoxetine in the treatment of attention deficit/hyperactivity disorder in children and adolescents. Eur Neuropsychopharmacol 2002; 12: S411
   Web of Science ®Google Scholar
• Greenhill LL, Swanson JM, Vitiello B, et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 180–187
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Abikoff HB, Arnold LE, et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry 1996; 35: 1304–1313
   PubMed Web of Science ®Google Scholar